CNBC's Stock Pops & Drops From October 29

, Karen Finerman said that she has a long position in

, which spiked 3.86 percent on Wednesday. Finerman picked this stock as her final trade on Tuesday and she still thinks that it is a buy. Pete Najarian explained that

dropped 5.93 percent on the news that its CEO was relieved of his duties and also because its diabetes drug is not living up to what people are expecting. He wouldn't buy the stock.

dropped 3.26 percent after posting earnings results and Guy Adami believes that this could be a buying opportunity. Dan Nathan said that it is probably necessary to consult lawyers to figure out how to trade

after the stock dropped 7.36 percent on the news that the company has lost the lawsuit and was forced in the mediation. Nathan thinks that it would be wise to buy when it drops to $30 from its current price of $34.